Literature DB >> 3922652

Clinical studies on plasma fibronectin and factor XIII; with special reference to hyperlipoproteinemia.

M Cucuianu, H G Rus, A Cristea, F Niculescu, D Bedeleanu, D Poruţiu, S Roman.   

Abstract

When compared to age-matched normal weight normolipidemic control subjects, plasma factor XIII, plasma fibronectin and serum cholinesterase levels were found to be markedly decreased in patients with decompensated cirrhosis of the liver, not significantly changed in hyperlipoproteinemia type IIa (heterozygous subjects) and increased in hypertriglyceridemic subjects (type IIb and IV) as well as in hyperlipidemic nephrotic patients. A possible accelerated hepatic synthesis of certain plasma proteins including factor XIII and fibronectin in patients with the nephrotic syndrome as well as in endogenous hypertriglyceridemia is envisaged. It is also considered that mural thrombi, richer in factor XIII and fibronectin, would be more resistant to fibrinolysis and more readily attached to subendothelial structures.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3922652     DOI: 10.1016/0009-8981(85)90210-4

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  1 in total

1.  Fibronectin decrease in liver cirrhosis is related to spleen size.

Authors:  V de Angelis; M Zambon; L Toffolo; C Donada; G L Molaro; R Zuin
Journal:  Klin Wochenschr       Date:  1988-06-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.